Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Stopped early · Phase 2

Conditions studied: Prostate Cancer

In brief

This is a correlative study to characterize serum metabolites associated with bone deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not currently receiving bone targeting agents.

Key facts

Study ID

NCT02758132

Run by

University of Hawaii

People needed

1

Starts

2016-03-01

Expected to finish

2016-09-06

Last updated by the study team

2019-11-08

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologic proof of adenocarcinoma of the prostate with clinical evidence of metastatic disease to the bone.
• Castrate resistant progression of prostate carcinoma, as shown by:
• Serum testosterone level <50 ng/dL or prior bilateral orchiectomy. Treatment to maintain castrate levels of testosterone should continue, and
• Either symptomatic progression, or, if patient is asymptomatic then a rising serum PSA in two occasions at least 1 week apart, with minimum pre-treatment serum PSA of 5 ng/dL.
• Patients with nodal disease are eligible.
• Bi-dimensionally measurable disease within the bone.
• Life expectancy of at least 12 weeks.
• ECOG Performance status < 2
• Adequate:
• Bone marrow function; absolute neutrophil count > 1,500 mm3, platelet count of > 100,000 mm3 and hemoglobin > 9.0 gm/dl.
• Hepatic function; SGOT/SGPT and conjugated bilirubin less than twice the upper limit of normal.
• Renal function; serum creatinine ≤ 2 mg/dL (or, if creatinine > 2 mg/dL, then a creatinine clearance of at least 35 ml/min (measured or estimated by the Cockroft formula:
• CLcr = [(140-age) x wt (kg)]/[72 x serum creatinine (mg/dL)].
• No evidence of coagulopathy as indicated by PT < 1.5X upper limit of normal.
• Serum calcium (corrected) from 8 to11.5 mg/dL (2 to 2.9 mmol/L) - Patients must sign an informed consent indicating that they are aware of the investigational nature of the study.

You may not qualify if…

• Patients with variant histologies (e.g., ductal or small cell carcinoma).
• Patients with visceral disease are ineligible.
• Patients who have had prior Sipuleucel-T, docetaxel, cabazitaxel, abiraterone or enzalutamide as a single agent, or in combination therapy.
• Concurrent cancer chemotherapy, radiotherapy or surgery.
• Concurrent serious infection.
• Life threatening illness (e.g., congestive heart failure, uncontrolled angina or myocardial infarction in the prior six months).
• Hypertension uncontrolled by medication.
• Patients who are known to require invasive dental procedures.
• No known or suspected brain metastases (NOTE: patients with treated epidural disease are allowed)
• Administration of any investigational drug within 28 days prior to receipt of denosumab.
• Age ≤ 18 years of age

Where it is running

• University of Hawaii Cancer Center — Honolulu, Hawaii, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.